Total Funding
69
76
Total FundingPost-IPO Equity raised
Growth Score 69 in past quarter
-7 pts
Heat Score 76 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4070
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
Darrell Irvine: Co-Founder, SAB memberPast Role: Stanford University, Postdoctoral Fellow- Robert Connelly: CEOPast Role: Axcella, CEO & Board Member
About the Company
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.